Novartis Navigates Metabolic Syndrome, Finds Link To Liver Disease
Executive Summary
Novartis is using the screening process for the NAVIGATOR study of Diovan and Starlix to connect metabolic syndrome with markers for liver disease, according to data presented at the American Heart Association annual meeting Nov. 16 in Dallas
You may also be interested in...
GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King
Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes
GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King
Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes
Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy
Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor